Tag : BRAF

Gastroenterology

Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation

Newsemia
Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation Source link...
Latest News

Researchers uncover cellular resistance mechanisms to BRAF inhibitors in melanoma

Newsemia
Melanoma is one of the most aggressive types of skin cancer, but recent advances in targeted therapies have improved the prognosis for many patients. Unfortunately,...
Latest News

Spirita Oncology, LLC Initiates a Phase 1 Clinical Trial of the Anti-Cancer Agent E6201 in Patients with Central Nervous System Metastases from BRAF+ or MEK-Mutated Metastatic Melanoma

Newsemia
BOSTON–(BUSINESS WIRE)–Spirita Oncology, LLC, has initiated a Phase 1 clinical trial of anti-cancer agent E6201 in patients with central nervous system metastases from BRAF- or...
Dermatology

Concordance of somatic mutation profiles [BRAF, NRAS and TERT] and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.

Newsemia
Related Articles Concordance of somatic mutation profiles [BRAF, NRAS and TERT] and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples. Hum Pathol. 2018...
Latest News

Pierre Fabre recibe una opinión positiva por parte de CHMP para BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) en pacientes adultos con melanoma con mutación de BRAF avanzado

Newsemia
CASTRES, Francia–(BUSINESS WIRE)–Pierre Fabre anunció hoy que el Comité de Medicamentos de Uso Humano (CHMP) de la Agencia Europea de Medicamentos (EMA) adoptó una opinión...
Latest News

Pierre Fabre reçoit un avis positif du CHMP pour le BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) pour les patients adultes atteints d'un mélanome à mutation BRAF au stade avancé

Newsemia
CASTRES, France–(BUSINESS WIRE)–Pierre Fabre a annoncé aujourd’hui que le Comité des médicaments à usage humain (CHMP) de l’Agence européenne des médicaments (EMA) avait adopté un...
Latest News

Pierre Fabre riceve un'opinione positiva dal CHMP su BRAFTOVI® (encorafenib) e MEKTOVI® (binimetinib) in associazione nel trattamento di pazienti adulti affetti da melanoma avanzato con mutazione BRAF

Newsemia
CASTRES, Francia–(BUSINESS WIRE)–Pierre Fabre ha annunciato oggi che il Comitato per i medicinali per uso umano (CHMP) dell’Agenzia europea dei medicinali (EMA) ha adottato un’opinione...
Latest News

Pierre Fabre recebe parecer positivo do CHMP para BRAFTOVI® (encorafenibe) + MEKTOVI® (binimetinibe) em pacientes adultos com melanoma mutante BRAF avançado

Newsemia
CASTRES, França–(BUSINESS WIRE)–A Pierre Fabre anunciou hoje que o Comitê de Produtos Medicinais para Uso Humano (CHMP) da Agência Europeia de Medicamentos (EMA) adotou um...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy